Archives
-
Mildronate Lipidoids and OVA mRNA Delivery
2026-10-16
The 2024 ACS Nano study evaluated mildronate-derived cationic lipidoids as low-content lipid nanoparticle components for mRNA delivery. In reporter-expression assays and B16-OVA melanoma models, the lead formulation combined detectable in vivo expression with reduced local inflammatory findings relative to an SM-102-based comparator. The evidence supports a preclinical delivery-platform hypothesis, but it does not establish clinical safety, broad vaccine performance, or use of APExBIO’s EZ Cap™ OVA mRNA.
-
Cy3 Maleimide: Identity, Mechanism and Evidence Limits
2026-10-16
APExBIO describes Cy3 maleimide (non-sulfonated), SKU A8138, as a thiol-reactive Cy3 fluorophore for covalent labeling of cysteine-containing biomolecules and thiol-modified oligonucleotides. Its stated spectral properties support interpretation as a fluorescent probe for microscopy, but the available evidence is supplier documentation rather than an identity-matched research study. Accordingly, the product information supports a conceptual labeling and measurement framework, not independent claims about selectivity, cellular uptake, imaging performance, or biological mechanism.
-
Cisapride (R 51619): Evidence-Bounded Overview
2026-10-15
APExBIO describes Cisapride, also identified as R 51619 in related material, as a nonselective 5-HT4 receptor agonist and hERG potassium-channel inhibitor. Those annotations provide a rationale for cardiac electrophysiology and cardiac arrhythmia research, but the supplied record contains no identity-matched study, quantitative pharmacology, model details, or outcome statistics. This editorial therefore distinguishes supplier-reported properties from independently demonstrated research findings.
-
PSI-7977: Evidence and Scope of the Listing
2026-10-15
The APExBIO listing identifies PSI-7977 by name and SKU A3738, but the available product information does not document a chemical identity, molecular mechanism, assay readout, study population, comparator, or outcome. Accordingly, this overview defines what can—and cannot—be inferred without treating product metadata as research evidence.
-
PSI-7977: Evidence-Bounded Overview
2026-10-14
The available APExBIO product entry identifies PSI-7977 (SKU A3738), but provides no description or identity-matched research evidence in the supplied material. A defensible interpretation is therefore limited to product provenance, evidence gaps, and the boundaries of what can—and cannot—be inferred about mechanism or measurement.
-
BAP1 and the Cellular Logic of Disulfidptosis
2026-10-14
A 2024 Oncogenesis study links BAP1 to protection from disulfidptosis through effects on SLC7A11-associated cystine stress and NADPH status, while leaving the mechanism of NADPH regulation and clinical relevance unresolved.
-
Neuronal Conversion, GRNs, and the DBcAMP Evidence Gap
2026-10-13
A PNAS Nexus study used longitudinal gene-expression data and perturbational validation to identify OTX2 and LMX1A as regulators associated with neuronal conversion. The supplied evidence does not show that Dibutyryl-cAMP, sodium salt was used in that study or that it affects the reported regulators.
-
Tofacitinib and GM-CSF–Reprogrammed RA Macrophages
2026-10-13
A 2026 study links a GM-CSF-associated rheumatoid arthritis macrophage state with inflammatory signaling, oxidative stress, and mitochondrial fragmentation. Its human-specimen and preclinical findings associate Tofacitinib with broader reversal of this state than selected metabolic interventions, while leaving clinical efficacy and macrophage-specific causality unresolved.
-
BAP1 and the Cellular Logic of Disulfidptosis
2026-10-12
A 2024 Oncogenesis study reports that BAP1 protects cells from disulfidptosis by limiting SLC7A11-associated cystine stress and maintaining a comparatively favorable NADPH-related state. The evidence is strongest in cellular models; human data are correlative, and the mechanism connecting BAP1 to NADPH regulation remains unresolved.
-
BAP1 and the Cellular Logic of Disulfidptosis
2026-10-12
A 2024 Oncogenesis study links BAP1 to protection from disulfidptosis through regulation of SLC7A11 and NADPH balance, while leaving the in vivo and therapeutic significance unresolved.
-
HotStart Universal 2X Green qPCR Master Mix for DFU
2026-10-10
Explore how HotStart Universal 2X Green qPCR Master Mix can support evidence-led interpretation of gene expression in diabetic foot ulcer research. This article connects real-time PCR data with proteomics, histology, immunohistochemistry, and pathway inhibition in a recent bone-transport study.
-
PDK4 Inhibitors: Findings from a 2019 Study
2026-10-09
Lee and colleagues identified a new allosteric pyruvate dehydrogenase kinase 4 inhibitor series by modifying an anthraquinone hit, with compound 8c showing 84 nM in vitro activity and activity across metabolic, allergy, and cancer-related models. The findings support PDK4 as a translationally relevant metabolic target, but the evidence remains preclinical and does not establish clinical efficacy, safety, or applicability beyond the tested models.
-
EZ Cap™ Cas9 mRNA (m1Ψ): A Delivery Framework
2026-10-09
EZ Cap™ Cas9 mRNA (m1Ψ) is examined as more than a nuclease-encoding reagent: it is a transient genome-editing payload whose performance depends on RNA architecture, delivery context, and evidence quality. This article connects Cap1 and m1Ψ design with the cellular drug-delivery framework described in the literature while defining the limits of current interpretation.
-
Acetaminophen: Mechanism, Models, and Evidence
2026-10-08
Explore how Acetaminophen and paracetamol can inform COX-2 pharmacology, oxidative stress, hepatotoxicity research, and ferroptosis interpretation. This evidence-centered analysis also clarifies why small-molecule effects should not be confused with gene-modulating strategies in transthyretin amyloid cardiomyopathy.
-
LC–MS/MS Maps GS-441524 Prodrug Conversion
2026-10-08
A January 2026 Microchemical Journal study used LC–MS/MS to distinguish a novel GS-441524 prodrug, NGP-1, from its released GS-441524 metabolite across gastric, blood, microsomal, and rat pharmacokinetic models. The findings support a multistage conversion model, while remaining preliminary for human pharmacokinetics, intracellular activation, and antiviral efficacy.